alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 601–625 of 27,380 studies, newest first · page 25 of 1096.

September 2026 18

  1. 2026-09-01

    A reproducibility-audit framework for generalizable versus dataset- specific molecular transition boundaries in Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed Digital health tools bioRxiv

    Key finding: Validated on synthetic ground truth, the audit separates a generalizable anchor (PTGDS) from a dataset-specific signal and a global-expression artefact, providing a reusable control for trajectory-based molecular staging. +4 more findings

    Scored 24 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  2. 2026-09-01

    The mediating effects of attitudes toward people with dementia on the relationship between caregiving burden and sense of competence among dementia care staff in Southern Chinese nursing homes: A cross-sectional study

    ⚠ Preprint — not yet peer-reviewed Caregiving Research Square

    Key finding: Our results showed that caregiving burden was negatively associated with the sense of ability.. +2 more findings

    Scored 39 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  3. 2026-09-01

    Does CSF testing add value after an indeterminate plasma p-tau217 result?

    ⚠ Preprint — not yet peer-reviewed Biomarkers Research Square

    Key finding: These data are compatible with, but do not establish, equivalence between plasma p-tau217 and CSF biomarkers. +4 more findings

    Scored 35 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  4. 2026-09 month only

    TMEM106B is a selective modulator of TDP-43 pathology in Alzheimer's disease

    ✓ Peer-reviewed Brain tissue and pathology Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: The TMEM106B risk variant was significantly enriched in AD cases with transactive response DNA-binding protein 43 kDa (TDP-43) pathology - associating with increased odds of developing AD TDP-43 subtype α - but failed to associate with Lewy body or vascular pathology. +2 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2026-09-01

    GRN rs5848 variant associates with TDP-43 pathology and cancer in opposite directions

    ✓ Peer-reviewed Brain tissue and pathology Journal of neuropathology and experimental neurology

    Key finding: The Granulin (GRN) gene single nucleotide variant rs5848 T allele is associated with increased risk of limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and hippocampal sclerosis of aging (HS-Aging). +3 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2026-09-01

    The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review

    ✓ Peer-reviewed Drug development JAMA psychiatry

    Key finding: These convergent data support a prospective clinical trial of low-dose lithium orotate to slow disease progression in MCI. +2 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2026-09 month only

    Digital dementia in adults: an assessment of digital generations

    ✓ Peer-reviewed Cognitive tests and assessment Central European journal of public health

    Key finding: The mean DDAF score was 40.56 ± 21.18 among digital natives (18-29 years), 34.93 ± 21.88 among the digital transition generation (30-44 years), and 25.17 ± 18.59 among digital immigrants (45-70 years) (p < 0.001). +4 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2026-09 month only

    Brain-derived plasma p-tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: All markers tracked neuropathological severity, with BD p-tau217 having larger fold-changes than p-tau217 but BD p-tau217/Aβ42 enhancing this further. +3 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2026-09-01

    Returning APOE and pTau-217 Results: the eSMARTER Randomized Noninferiority Clinical Trial

    ⚠ Preprint — not yet peer-reviewed Genetics medRxiv (preprint)

    Key finding: ImportancePatients are increasingly learning Alzheimers disease (AD) genetic and biomarker results through electronic health portals. +4 more findings

    Scored 33 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  10. 2026-09-01

    Presynaptic accumulation of APP-CTFβ may contribute to synaptic dysfunction in Alzheimer’s disease

    ✓ Peer-reviewed Disease mechanisms The EMBO Journal

    Key finding: Brain recordings have revealed synaptic hyperexcitation during asymptomatic and early stages of AD, reverting to overinhibition as dementia progresses. +2 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2026-09-01

    Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

    ✓ Peer-reviewed Treatments Alzheimer s & Dementia

    Key finding: One phenotype (18% of Aβ+ participants) showed the steepest cognitive decline, highest progression on the CDR, greater baseline medial temporal tau, and fastest neocortical tau accumulation over 4.6 years (hazard ratio [HR] for decline ≈ 2.9). +2 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2026-09-01

    Regional Distribution of Mineralized Blood Vessels in Alzheimer Disease and Clinicopathological Associations: A Multicenter Autopsy Study

    ✓ Peer-reviewed Genetics Neurobiology of Aging

    Key finding: Mineralized blood vessels (MBV) are a form of vascular pathology associated with cerebrovascular aging and neurodegeneration; however, their regional distribution and clinicopathological correlates in Alzheimer disease (AD) remain poorly characterized. +3 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2026-09-01

    Psychological impacts of APOE genotype disclosure among Latinos in New York City: a randomized controlled trial

    ✓ Peer-reviewed Genetics Alzheimer s & Dementia

    Key finding: Disclosure (N = 194) and non-disclosure (N = 180) groups did not differ on IGT-AD (mean disclosure-non-disclosure difference [MD] at 6 weeks: -1.5, p = 0.14; 9 months: -1.2, p = 0.35; 15 months: -2.0, p = 0.07), IES-R (MD at 6 weeks: 0.00, p = 0.98; 9 months: 0.01, p = 0.84; 15 months: 0.03, p = 0.64), or change in secondary outcomes. +3 more findings

    Full summary, score breakdown and related studies → Original source

  14. 2026-09-01

    Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study

    ✓ Peer-reviewed Biomarkers The Lancet Neurology

    Key finding: The study included 197 patients in whom lecanemab infusions had been started (lecanemab group), as well as 173 patients in whom lecanemab had been ordered but not yet started, who were combined with 1139 research participants with cognitive impairment from the Knight ADRC cohort to form the untreated control group with cognitive impairment (n=1312). +4 more findings

    Full summary, score breakdown and related studies → Original source

  15. 2026-09-01

    CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS-FTD Spectrum: A Systematic Narrative Review and Evidence Map

    ✓ Peer-reviewed Tau biomarkers Brain and behavior

    Key finding: Cognitive impairment is an important non-motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS-frontotemporal dementia (ALS-FTD) spectrum. +3 more findings

    Full summary, score breakdown and related studies → Original source

  16. 2026-09-01

    Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome

    ✓ Peer-reviewed Down syndrome and Alzheimer's Neurology

    Key finding: In DS, longitudinal characterization of all previously identified proteins revealed distinct trajectories over time and an association of baseline levels with future cognitive decline. +4 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2026-09-01

    Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

    ✓ Peer-reviewed Down syndrome and Alzheimer's Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: There is a need for early, objective markers of Alzheimer's disease (AD)-related synapse dysfunction in adults with Down syndrome (DS).

    Full summary, score breakdown and related studies → Original source

  18. 2026-09 month only

    Domain-specific physical activity levels and risk of dementia: a systematic review and meta-analysis

    ✓ Peer-reviewed Prevention and risk The Lancet. Public health

    Key finding: Over a median follow-up of 10·0 years (IQR 5·1-21·3), high physical activity levels were associated with reduced risks of all-cause dementia (n=146 effect sizes; RR 0·80 [95% CI 0·75-0·86]; I 2 =97·4%), Alzheimer's disease (n=59; 0·79 [0·70-0·90]; I 2 =91·3%), and vascular dementia (n=21; 0·71 [0·58-0·87]; I 2 =77·5%); however, associations varied by domain. +2 more findings

    Full summary, score breakdown and related studies → Original source

August 2026 7

  1. 2026-08-31

    The Association of Thrombophilic and Cardiovascular Genetic Variations with Neurovascular and Neurodegenerative Diseases: A Multivariate Genetic and Clinical Analysis

    ⚠ Preprint — not yet peer-reviewed Cognitive tests and assessment Preprints.org

    Key finding: MTHFR C677T homozygosity was independently associated with vascular dementia (OR 3.2; 95% CI 1.1–8.9; p=0.027) and showed clustering with cognitive impairment. +4 more findings

    Scored 26 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  2. 2026-08-31

    Neuroexposomics to Prevent Neurodegenerative Disease: Challenges, Next Steps, and Recommendations

    ⚠ Preprint — not yet peer-reviewed How common it is Preprints.org

    Key finding: It offers great potential to be meaningfully translated into reductions in the incidence of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. +4 more findings

    Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  3. 2026-08-31

    Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration

    ⚠ Preprint — not yet peer-reviewed Lewy body dementia bioRxiv

    Key finding: Here, we evaluate its utility in sporadic and familial FTLD compared to other neurodegenerative diseases. +2 more findings

    Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  4. 2026-08-31

    Reduced Dementia Incidence Following Neck Dissection: A Population-based Matched Cohort Study

    ⚠ Preprint — not yet peer-reviewed Digital health tools Research Square

    Key finding: Among 9,386 propensity score-matched pairs of ND patients and controls, covariates were well balanced. +4 more findings

    Scored 39 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  5. 2026-08-31

    The Gut-Brain Axis in Alzheimer’s Disease: Microbiota as a Key Contributor to Disease Pathogenesis

    ⚠ Preprint — not yet peer-reviewed Disease mechanisms Preprints.org

    Key finding: Increasing evidence indicates that the gut microbiota composition is a key modulator of AD pathogenesis, driving neuroinflammation, and amyloid and tau pathology through the microbiota–gut–brain axis.

    Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  6. 2026-08-31

    Afternoon Spectral Reddening of Daylight as a Candidate Physical Cue for Sundowning Syndrome

    ⚠ Preprint — not yet peer-reviewed Brain scans and imaging Preprints.org

    Key finding: The short-wavelength content of available light declines steadily through the afternoon, well before nightfall, while the long-wavelength component remains nearly constant. +3 more findings

    Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  7. 2026-08-31

    Clinical expression beyond measured Alzheimer disease molecular pathology: a discovery and external evaluation study

    ⚠ Preprint — not yet peer-reviewed Brain scans and imaging Research Square

    Key finding: A prespecified structure–reserve–glial profile captured reproducible cognitive variation beyond measured Alzheimer disease molecular pathology across two cohorts.

    Scored 47 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →